Perazine

Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. It is quite similar to chlorpromazine, and acts as a dopamine antagonist. A 2014 systematic review compared it with other antipsychotic drugs:

Perazine versus other antipsychotic drugs for schizophrenia[1]

Summary
The number, size and reporting of randomized controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side effects as some atypical antipsychotics but this is based on few comparisons of limited power.[1]
Outcome Findings in words Findings in numbers Quality of evidence Global state No better or deterioration Follow-up: average 5 weeks Perazine may decrease the chance of experiencing this outcome. These findings are based on data of low quality. RR 0.43 (0.23 to 0.81) Low Mental state Less than 30% BPRS reduction Follow-up: mean 5 weeks The average overall mental state score in the perazine group was lower than for those given other antipsychotic drugs but the difference between the groups was not clear. These findings are based on data of low quality. RR 0.82 (0.61 to 1.09) Low Adverse effects Needing antiparkinson medication Follow-up: average 5 weeks Perazine might increase the risk of experiencing this outcome but at present it is not possible to be confident about the difference between perazine and other antipsychotic drugs. Data supporting this finding are very limited. RR 4.5 (1.04 to 19.45) Very low Leaving the study early - due to adverse events Follow-up: average 4 weeks There was not a clear difference between perazine and the other antipsychotic drugs for this general outcome reflecting overall adverse event 'load'. These findings are based on data of low quality. 0.87 (0.4 to 1.9) Low Acceptability of treatment Leaving the studies early - any reason Follow-up: 5 weeks Perazine and the comparison antipsychotic drugs were equally tolerated. These findings are based on data of low quality. RR 0.62 (0.35 to 1.1) Low No study reported any data on outcomes such as quality of life or information relating to satisfaction with care.

Perazine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N05AB10 (WHO)
Identifiers
IUPAC name 10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
CAS Number	84-97-9
PubChem CID	4744
ChemSpider	4582
UNII	8915147A2B
ChEBI	CHEBI:59118
CompTox Dashboard (EPA)	DTXSID6048628
ECHA InfoCard	100.001.435
Chemical and physical data
Formula	C20H25N3S
Molar mass	339.50 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42
InChI InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3 Key:WEYVCQFUGFRXOM-UHFFFAOYSA-N
(what is this?)  (verify)

See also

• Carphenazine
• Dixyrazine
• Methdilazine
• Pipamazine

References

1. Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". The Cochrane Database of Systematic Reviews. 1 (1): CD002832. doi:10.1002/14651858.CD002832.pub3. PMID 24425538.

External links

• Perazine at the US National Library of Medicine Medical Subject Headings (MeSH)